Pharmaceutical - Cipla


Current filters:


Popular Filters

Indian govt to penalize drugmakers for overcharging

Indian govt to penalize drugmakers for overcharging


In a major crackdown, India's drug price regulator, the National Pharmaceutical Pricing Authority (NPPA)…


Merck & Co partners with Cipla for Indian marketing of raltegravir

Merck & Co partners with Cipla for Indian marketing of raltegravir


US pharma giant Merck & Co, known as MSD outside North America, has announced the formation of an India-specific…

Anti-viralsAsia-PacificCiplaIndiaIsentressMarkets & MarketingMerck & CoPharmaceuticalRaltegravir Tablets

Report: Indian pharma companies’ innovation is increasing but fails to match Europe


Innovation by Indian pharmaceutical companies has increased over the last few years but has not demonstrated…

CiplaDr Reddy's LaboratoriesIndiaPatentsPharmaceuticalResearch

Meda expands collaboration with India's Cipla on Dymista


Swedish drugmaker Meda (OMX: MEDA A) is broadening its collaboration with Indian pharmaceutical company…

Asia-PacificCiplaDymistaLicensingMedaPharmaceuticalRespiratory and PulmonaryRest of the WorldSouth America

Indian IPAB provides relief for Pfizer in Sutent patent revocation case


India's Intellectual Property Appellate Board (IPAB) has provided global pharma behemoth Pfizer (NYSE:…


India's Cipla ups bid for Cipla Medpro now seeking 100% control for around $512 million


Indian drugmaker Cipla (BSE: 500087) has made an offer to the shareholders of Cipla Medpro South Africa…

CiplaCipla MedproGenericsMarkets & MarketingPharmaceutical

India's Cipla cuts prices of three cancer drugs


Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Another negative Indian patent ruling, this time for Pfizer's Sutent


In yet another setback for research-based pharmaceutical companies, last week the Indian patent office…

Asia-PacificCiplaGenericsLegalNatco PharmaOncologyPatentsPfizerPharmaceuticalSutent

DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination


Coinciding with the XIX International AIDS Conference in Washington DC, the Drugs for Neglected Diseases…


Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too


Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

Back to top